NO20065107L - PGD2 receptor antagonists for the treatment of inflammatory diseases - Google Patents

PGD2 receptor antagonists for the treatment of inflammatory diseases

Info

Publication number
NO20065107L
NO20065107L NO20065107A NO20065107A NO20065107L NO 20065107 L NO20065107 L NO 20065107L NO 20065107 A NO20065107 A NO 20065107A NO 20065107 A NO20065107 A NO 20065107A NO 20065107 L NO20065107 L NO 20065107L
Authority
NO
Norway
Prior art keywords
treatment
receptor antagonists
inflammatory diseases
pgd2 receptor
structural formulas
Prior art date
Application number
NO20065107A
Other languages
Norwegian (no)
Inventor
Amy M Elder
Kevin Sprott
Sean Harrison
Shomir Ghosh
Dominic Reynolds
Kenneth G Carson
Frederick A Hicks
Christelle C Renou
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NO20065107L publication Critical patent/NO20065107L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Beskrevet her er forbindelser representert ved Strukturelle Formel (I) og (I-A): Også beskrevet er anvendelse av slike forbindelser for å hemme G-protein koblet reseptor referert til som kjemotiltrekkende reseptor-homolog molekyl uttrykt på Th2 eller kun "CRTH2" for behandling av inflammatoriske lidelser. Variablene i Strukturelle Formel (I) og (I-A) er definert her.Described herein are compounds represented by Structural Formulas (I) and (IA): Also disclosed is the use of such compounds to inhibit G protein coupled receptor referred to as chemo-attracting receptor homologous molecule expressed on Th2 or only "CRTH2" for the treatment of inflammatory disorders. The variables in Structural Formulas (I) and (I-A) are defined here.

NO20065107A 2004-04-07 2006-11-06 PGD2 receptor antagonists for the treatment of inflammatory diseases NO20065107L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56041004P 2004-04-07 2004-04-07
PCT/US2005/011643 WO2005100321A1 (en) 2004-04-07 2005-04-07 Pgd2 receptor antagonists for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
NO20065107L true NO20065107L (en) 2006-12-01

Family

ID=34965223

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065107A NO20065107L (en) 2004-04-07 2006-11-06 PGD2 receptor antagonists for the treatment of inflammatory diseases

Country Status (21)

Country Link
EP (1) EP1740547A1 (en)
JP (1) JP2007532555A (en)
KR (1) KR20070002085A (en)
CN (1) CN101018770A (en)
AR (1) AR048528A1 (en)
AU (1) AU2005233125A1 (en)
BR (1) BRPI0509668A (en)
CA (1) CA2561564A1 (en)
CL (1) CL2008000069A1 (en)
CR (1) CR8659A (en)
EC (1) ECSP066977A (en)
IL (1) IL178328A0 (en)
MA (1) MA28566B1 (en)
MX (1) MXPA06011540A (en)
NO (1) NO20065107L (en)
RU (1) RU2006138603A (en)
TN (1) TNSN06320A1 (en)
TW (1) TW200538127A (en)
UA (1) UA84749C2 (en)
WO (1) WO2005100321A1 (en)
ZA (1) ZA200608955B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070114762A (en) 2005-02-24 2007-12-04 밀레니엄 파머슈티컬스 인코퍼레이티드 Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
RU2422442C2 (en) 2005-07-29 2011-06-27 Ф. Хоффманн-Ля Рош Аг Indole-3-yl-carbonyl-piperidine and piperazine derivatives
ES2618352T3 (en) 2006-06-16 2017-06-21 The Trustees Of The University Of Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of androgenetic alopecia
JP2010501567A (en) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 2- (pyrazin-2-yl) -thiazole and 2- (1H-pyrazole-3-) as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders Yl) thiazole derivatives and related compounds
JPWO2008029924A1 (en) 2006-09-08 2010-01-21 大日本住友製薬株式会社 Cyclic aminoalkylcarboxamide derivatives
EP2066664A1 (en) 2006-09-22 2009-06-10 Novartis AG Heterocyclic organic compounds
KR20090091337A (en) 2006-12-20 2009-08-27 노파르티스 아게 2-substituted 5-membered heterocycles as scd inhibitors
JP5466507B2 (en) 2007-09-27 2014-04-09 興和株式会社 A prophylactic and / or therapeutic agent for anemia comprising a tetrahydroquinoline compound as an active ingredient
AU2008337342B2 (en) 2007-12-14 2012-05-24 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
JP2011102241A (en) * 2008-03-04 2011-05-26 Dainippon Sumitomo Pharma Co Ltd Novel 1-aminocarbonylpiperidine derivative
ES2617868T3 (en) 2008-08-22 2017-06-20 Baxalta GmbH Polymeric benzyl carbonate derivatives
JP2011256110A (en) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd Manufacturing method of hexahydropyrroloquinoline
EP2415764A4 (en) 2009-03-31 2012-08-08 Kowa Co Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2955524A3 (en) 2009-11-05 2016-03-23 GlaxoSmithKline LLC Novel process
BR112013000254A2 (en) 2010-07-05 2016-05-24 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclic derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
MX2013014900A (en) 2011-06-17 2014-02-17 Merck Sharp & Dohme Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators.
BR112014014558A8 (en) 2011-12-16 2017-07-04 Atopix Therapeutics Ltd pharmaceutical composition, use of a crth2 antagonist and a proton pump inhibitor, and kit for the treatment of eosinophilic esophagitis
BR112014015081A2 (en) 2011-12-21 2017-06-13 Actelion Pharmaceuticals Ltd heterocyclic derivatives and their use as prostaglandin d2 receptor modulators
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
CA2993972A1 (en) 2015-07-30 2017-02-02 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
JOP20190105A1 (en) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
EA202092490A1 (en) 2018-04-18 2020-12-23 Констеллейшен Фармасьютикалс, Инк. METHYL-MODIFYING ENZYMES MODULATORS, COMPOSITIONS AND THEIR APPLICATION
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN113201316B (en) * 2021-04-25 2022-08-26 西南石油大学 temperature/CO 2 pH multi-responsive emulsifier and emulsion and application thereof
CN116425623B (en) * 2023-04-10 2024-02-13 大连凯飞化学股份有限公司 Method for synthesizing 3,5-dichloro-4-methylbenzoic acid by one-pot method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101728A3 (en) * 1998-03-31 2002-04-29 Shionogi & Co 5-hydroxybenzo[b]thiophene-3-carboxylic acid and their derivatives and methods for producing them
CN1297541C (en) * 2001-04-30 2007-01-31 辉瑞产品公司 Method for preparing CETP inhibitors
JP2003321471A (en) * 2002-04-30 2003-11-11 Fuji Photo Film Co Ltd Lactam compound and method of production for the same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
EA011385B1 (en) * 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Pgd2 receptor antagonists for the treatment of inflammatory diseases
CA2500083A1 (en) * 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
AU2003289207A1 (en) * 2002-12-06 2004-06-30 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists

Also Published As

Publication number Publication date
ZA200608955B (en) 2009-05-27
BRPI0509668A (en) 2007-10-09
AR048528A1 (en) 2006-05-03
CR8659A (en) 2007-06-08
RU2006138603A (en) 2008-05-20
MXPA06011540A (en) 2007-01-26
CL2008000069A1 (en) 2008-05-16
KR20070002085A (en) 2007-01-04
EP1740547A1 (en) 2007-01-10
CA2561564A1 (en) 2005-10-27
IL178328A0 (en) 2007-02-11
UA84749C2 (en) 2008-11-25
CN101018770A (en) 2007-08-15
ECSP066977A (en) 2006-12-29
AU2005233125A1 (en) 2005-10-27
MA28566B1 (en) 2007-05-02
WO2005100321A1 (en) 2005-10-27
JP2007532555A (en) 2007-11-15
TNSN06320A1 (en) 2008-02-22
TW200538127A (en) 2005-12-01

Similar Documents

Publication Publication Date Title
NO20065107L (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
NO20051566L (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
NO20070489L (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors.
BRPI0408369A (en) indole derivatives useful for treating disease
NO20070466L (en) Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists
NO20064151L (en) New connections
NO20083411L (en) Indanacetic acid derivatives and their use as pharmaceutical agents, intermediates and methods of preparation
NO20070467L (en) Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as CRF antagonists
NO20063928L (en) Substituted quinoline compounds
CY1106894T1 (en) Sulfonamide derivatives for the treatment of diseases
DE602005013822D1 (en) CYCLOALKYLAMINDERIVATE
EA200200921A1 (en) Malonic Acid Polyamides and Their Derivatives as Ligands of Thyroid Receptors
ATE250577T1 (en) INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS
NO20065678L (en) 3- (4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors.
MX2007003335A (en) Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof.
WO2005018529A3 (en) Phenoxiacetic acid derivatives
NO20053792L (en) Heterocycly-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
EA201171197A8 (en) SUBSTITUTED DERIVATIVES AZOANTHRACENE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION
NO20052595L (en) Compositions useful as inhibitors of ROCK and other protein kinases.
NO20076059L (en) 2,4-Diamino-pyrimidines used as aurora inhibitors
NO20051503L (en) Pyrazolopyridines and processes for the preparation and use of the same.
NO20065230L (en) Condensed pyridine derivatives useful as A28 adenosine receptor antagonists
NO20065983L (en) Compounds and compositions as PPAR modulators
ATE478856T1 (en) SPIROBENZODIOXOLS AND THEIR USE AS CB1 ANTAGONISTS
NO20076515L (en) hydantoin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application